VKTX Stock Gives Back Buyout Speculation-Spurred Gains, Investors Continue To Await Key Obesity Trial Topline Data
For VKTX investors, the main focus is the expected VANQUISH trial topline data readout in 2027. VKTX stock on Friday climbed after M&A-focused blog BetaVille discussed takeover rumors about the obesity-drug developer. The company announced fresh clinical data from two of its trials over the weekend, but it failed to buoy the rally on Monday. … Read more